Figure 5

CCL20 enhances the metastatic ability of breast cancer cells. (a) Viabilities of breast cancer cells stimulated with the indicated concentrations of CCL20 for 24, 48, and 72 h. (b–d) Quantity of 5-bromo-2′-deoxyuridine (BrdU) incorporated into newly synthesized DNA (b), migration (c), and invasion (d) in MDA-MB-231 cells stimulated with the indicated concentrations of CCL20 for 24 h. (e,f) MMP-1, MMP-2/9 (e), and uPA (f) activities in conditioned media from MDA-MB-231 cells stimulated with the indicated concentrations of CCL20 for 24 h. MMP-1 and MMP2/9 activities were determined by collagen and gelatin zymography, respectively. The clear bands indicate the activities of the MMPs. uPA activity was measured with a commercial uPA activity assay kit. (g,h) Invasion (g) and MMP-2 and MMP-9 activities in conditioned media (h) of MCF-7, ZR-75-1, BT549, and HCC38 breast cancer cells stimulated with CCL20 (200 ng/ml) for 24 h. The data are expressed as the mean ± s.e.m. *P < 0.05, **P < 0.01 versus cells without CCL20.